Compare Natera Inc. Common Stock (NTRA) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $58.7 (market cap $168.50B). The key difference: Vanguard Emerging Markets Stock Index Fund ETF is far larger — about 3× Natera Inc. Common Stock's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Vanguard Emerging Markets Stock Index Fund ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Vanguard Emerging Markets Stock Index Fund ETF for 135 Days on average.
| NTRA | VWO | |
|---|---|---|
Market Cap | $57.03B | $168.50B |
Volume | 1,131,157 | 5,873,453 |
Sector | Health | — |
52-Week High | $425.64 | $61.44 |
52-Week Low | $179.42 | $52.42 |
Typical Hold Time | 0 Days | 135 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
VWO trades at $59.68, down slightly by 0.08% today. Technical indicators show a neutral overall signal with bearish moving averages, while RSI readings are neutral. The ETF focuses on emerging markets, with exposure to Taiwan's AI and semiconductor sectors but faces headwinds from China's economic slowdown. Recent news highlights institutional buying interest, such as Allianz increasing its stake by 12.6% in Q3 2026.
Outlook is mixed: AI-driven growth in Taiwan offers upside, but China's weakness and concentration risks pose challenges. The ETF's low expense ratio of 0.06% appeals for cost-conscious investors, yet emerging market volatility requires caution. Key risks include regional economic instability and currency fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
